Donald Wilson, Jr. Biography and Net Worth

Major Shareholder of Aptose Biosciences

Mr. Donald Wilson, Jr. is the Major Shareholder of Aptose Biosciences.

How do I contact Donald R. Wilson, Jr. ?: The corporate mailing address for Mr. Wilson, Jr. and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Donald R. Wilson, Jr. 's contact information.
Has Donald R. Wilson, Jr. been buying or selling shares of Aptose Biosciences?: Donald R. Wilson, Jr. has not been actively trading shares of Aptose Biosciences during the last quarter. Learn More on Donald R. Wilson, Jr. 's trading history.
Who are Aptose Biosciences' active insiders?: Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.
Are insiders buying or selling shares of Aptose Biosciences?: In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $20,000.00. The most recent insider tranaction occured on November, 25th when CEO William G Rice bought 100,000 shares worth more than $20,000.00. Insiders at Aptose Biosciences own 3.9% of the company. Learn More about insider trades at Aptose Biosciences.
Information on this page was last updated on 11/25/2024.

Donald R. Wilson, Jr. Insider Trading History at Aptose Biosciences

Donald R. Wilson, Jr. Buying and Selling Activity at Aptose Biosciences

Aptose Biosciences Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: $0.28

$0.21

$0.39

50 Day Range

MA: $0.30

$0.17

$0.40

2 Week Range

Now: $0.28

$0.13

$2.68

Volume

304,802,594 shs

Average Volume

1,745,122 shs

Market Capitalization

$16.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol